Mbx Biosciences, INC. (MBX) — 10-Q Filings
All 10-Q filings from Mbx Biosciences, INC.. Browse 4 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (4)
-
MBX Biosciences Boosts Cash by $173.8M, Losses Mount Amid R&D Push
— Nov 6, 2025 Risk: high
MBX Biosciences, Inc. (MBX) reported a significant increase in its cash and cash equivalents, reaching $223.1 million as of September 30, 2025, up from $49.3 mi -
MBX Biosciences' Q2 Loss Widens Amid R&D Push
— Aug 7, 2025 Risk: high
MBX Biosciences, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company posted a net l -
MBX Biosciences Files Q1 2025 10-Q
— May 12, 2025 Risk: medium
MBX Biosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position and business operations. Key events an -
MBX Biosciences Files Q3 2024 10-Q
— Nov 7, 2024 Risk: medium
MBX Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial position, including common stock and prefer
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX